Innovative Steps by Purple Biotech at EACR 2025
In a significant stride for cancer research, Purple Biotech Ltd. (NASDAQ/TASE: PPBT), a trailblazer in the development of groundbreaking therapies aimed at counteracting tumor immune evasion and drug resistance, is set to showcase its latest advancements. At the Annual Congress of the European Association for Cancer Research (EACR) 2025, the Company will present its novel CAPTN-3 tri-specific antibody platform, further solidifying its commitment to transforming oncology treatments.
Key Details of the Presentation
The poster presentation details are as follows:
Abstract #: EACR25-1964
Title: “CAPTN-3: A novel platform of conditionally activated T cell and NK cell engagers”
Session Title: Immunotherapy
Session Date and Time: June 17, 2025, from 10:45 to 20:00
Presenting Author: Dr. Hadas Reuveni, Vice President of R&D, Purple Biotech
Attendees will gain insights into the latest research and the innovative breakthroughs that could change the landscape of cancer treatment, aiming to unleash a powerful immune response within the tumor microenvironment.
Understanding the CAPTN-3 Technology
The CAPTN-3 platform is designed to engage both T cells and natural killer (NK) cells, orchestrating a robust immune response that is localized within the tumor. This approach effectively confines therapeutic activity to the tumor microenvironment. By doing so, it aims to enhance the anticipated therapeutic window for patients undergoing treatment. A particularly exciting feature of this platform is its ability to target Tumor Associated Antigens (TAA), presenting a novel mechanism of action that rallies both the innate and adaptive immune systems for a comprehensive anti-tumoral response.
Insights into Purple Biotech's Oncology Pipeline
Purple Biotech's commitment to advancing oncology treatments goes beyond the CAPTN-3 platform. The Company also boasts an impressive portfolio that includes CM24 and NT219. CM24, a humanized monoclonal antibody, has shown promising results in blocking CEACAM1, a key player in tumor immune evasion. This innovative approach has demonstrated efficacy, particularly in combination therapies targeting pancreatic ductal adenocarcinoma, where it was tested alongside nivolumab and chemotherapy, achieving significant improvements.
NT219, a novel small molecule dual inhibitor, has also showcased potential, especially in combination with cetuximab for metastatic head and neck cancers. Building on the encouraging results from Phase 1 studies, Purple Biotech is advancing NT219 into Phase 2 studies with plans to collaborate with the University of Colorado for further patient treatment options.
Looking Ahead: What’s Next for Purple Biotech
The Company’s groundbreaking approach to cancer immunotherapy paves the way for future advancements, not just within CAPTN-3 but across its entire pipeline. The ongoing research reflects a wider trend in oncology aimed at harnessing the potential of the immune system in fighting cancer more effectively.
As they prepare for the EACR conference, Purple Biotech is poised not just to share their findings but to collaborate with other innovators in the field, ultimately aspiring to save lives through advanced research and development.
Frequently Asked Questions
What is CAPTN-3?
CAPTN-3 is a novel platform developed by Purple Biotech that uses tri-specific antibodies to engage T cells and NK cells, promoting a strong immune response within tumors.
Who is presenting at the EACR 2025?
Dr. Hadas Reuveni, Vice President of R&D at Purple Biotech, will present the poster on CAPTN-3 at the EACR 2025 conference.
What are the key benefits of the CAPTN-3 technology?
This technology aims to enhance the therapeutic window for patients by localizing antibody activity within the tumor microenvironment.
What other therapies is Purple Biotech developing?
Purple Biotech is also developing CM24 and NT219, therapies designed to overcome tumor immune evasion and improve treatment outcomes in oncology.
How does Purple Biotech engage in clinical research?
Purple Biotech collaborates with various institutions and conducts clinical trials to advance their innovative therapies, ensuring rigorous testing and validation.
